The initiation of this trial does not trigger a milestone payment. The Phase II clinical trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, as well as potential efficacy, of the niacin receptor agonist in patients with dyslipidemia.
Jack Lief, president and CEO of Arena, said: “We are pleased with Merck’s decision to advance this niacin receptor agonist into Phase II. We look forward to the Phase II results and to the possible continued advancement of this program.”